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Soluble urokinase receptor (suPAR) is
proposed as circulating factor in focal
and segmental glomerulosclerosis (FSGS)
(1). Spinale et al. attempt to validate the
role of suPAR in glomerular disease (2).
Their mouse overexpression experiments
of physiological suPAR forms are dis-
tinct from the studies by Wei et al. that
expressed either alternate suPAR forms
or used different mouse models (1).
Additional experiments will help to fur-
ther clarify the distinct roles of suPAR
variants.
Spinale et al. extend previous clinical
studies indicating that glomerular filtra-
tion rate (GFR) is an important determi-
nant of suPAR (3). This, however, does
not imply that suPAR is only bystander, as
illustrated by epidemiological studies link-
ing elevated suPAR – independent of the
eGFR – to cardiovascular disease in patients
with CKD (4).
FIGURE 1 | suPAR plasma levels above cut off of 3000pg/ml in patients with eGFR >40ml/min
(blue line) as suggested by Li et al. applied to the patient cohort by Spinale et al. These values are
likely not explained by reduced GFR alone. Elevated suPAR level in preserved renal function patients
(orange line) is likely not dependent on eGFR.
As for most large protein plasma com-
ponents, the balance between generation
and clearance determines suPAR accumu-
lation, adding complexity when studying
the direct renal effects of suPAR, espe-
cially when possibly also causing kidney
disease. Biopsy proven FSGS patients with
GFR >40 ml/min have in 50% elevated
suPAR levels (5), suggesting also suPAR
production. In addition, suPAR fragments
(measured and unmeasured) may cause
podocyte injury, potentially contributing
to a reduced GFR. The strong effect of a
low GFR on serum suPAR levels in obser-
vational studies could obfuscate the effects
of suPAR-induced glomerular pathology.
In conclusion, dependence of serum
suPARlevelsonGFRprecludesusingsuPAR
as a single value biomarker for FSGS in
conditions of low GFR, but this correlation
does not serve as an explanation for elevated
suPAR under preserved GFR (Figure 1).
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